TCRR News and Press, TCR2 Therapeutics Inc. From 08/12/20

- TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75% - Began dosing of TC-110 in the Phase 1/2 trial for patients with CD19+ NHL or adult ALL - Addition of MD Anderson Cancer Center, a leading clinical site...

The following slide deck was published by TCR2 Therapeutics Inc. in conjunction with this Read more ...

Chimeric antigen receptor T-cell therapies to fight cancer have been around for a decade, but pharmaceutical companies are just beginning to scratch the surface on their potential applications. In a CAR T-cell therapy, a person's T-cells -- part of the immune system -- are modified by implantin...

TCR 2 Therapeutics (NASDAQ: TCRR ) has priced its public offering of 8M common shares at $15.50/share, for expected gross proceeds of $124M. More news on: TCR2 Therapeutics Inc., Healthcare stocks news, IPO News, , Read more ...

CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR 2 ” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the prici...

Radius Health inks licensing deal for elacestrant Radius Health Inc. ( RDUS ) announced that it has inked an exclusive global license agreement with privately-held Menarini for developing and commercializing of elacestrant. The drug candidate is currently being assessed in a Phase 3 study as...

TCR2 Therapeutics ( TCRR ) announced positive results of a Phase 1 trial on Monday , and the stock price is up over 50% in pre-market trading: Source: Google Finance TCR2's results may be promising indeed, but for the reasons stated below, traders and shareholders should be concerned abou...

CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR 2 ” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it h...

Shares of TCR2 Therapeutics (NASDAQ: TCRR) -- a clinical-stage biotech company that focuses on cancer treatments -- are up by 29.6% as of 11:34 a.m. EDT on Monday following the company's release of interim data for an ongoing clinical trial for one of its leading pipeline candidates. TCR2 T...

Socket Mobile (NASDAQ: SCKT ) +142%  on launching 2 barcode scanners. More news on: Socket Mobile, Inc., Wilhelmina International, Inc., TCR2 Therapeutics Inc., Stocks on the move, , Read more ...